| Figure 1. | The Evolution of National Kidney Foundation Guidelines for the Management of Dyslipidemias in Patients With Chronic Kidney Disease |
| Figure 2. | Ages Covered by the Current Guidelines, and Those Covered by Previous Guidelines Developed for Use in the General Population |
| Figure 3. | The Chain of Logic for Evidence Supporting the Treatment of Low-Density Lipoprotein Cholesterol in Patients With Chronic Kidney Disease |
| Figure 4. | The Relative Coronary Heart Disease Risk Reduction in Subgroups of Patients From Major Lipid-Lowering Trials in the General Population |
| Figure 5. | Causes of Death Among Period Prevalent Patients 1997-1999, Treated With Hemodialysis, Peritoneal Dialysis, or Kidney Transplantation |
| Figure 6. | Example Demonstrating the Relative Contributions of VLDL and IDL Remnants to Non-HDL Cholesterol in Two Hypothetical Patients With Normal and High Triglycerides, Respectively |
| Figure 7. | The Approach to Treatment of Dyslipidemias in Adults With Chronic Kidney Disease Used in These Guidelines |
| Figure 8. | The Approach to Treatment of Dyslipidemias in Adolescents With Chronic Kidney Disease Used in These Guidelines |
| Figure 9. | Expected Responses to Treatment of Low-Density Lipoprotein (Upper Panel), High-Density Lipoprotein (Middle Panel), and Triglycerides (Lower Panel), Based on Studies in the General Population |